Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Challenger ( (AU:CGF) ) is now available.
Challenger Limited has notified the ASX that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd, formally lodging the required notice under the Corporations Act. The change, covering Challenger and a range of associated entities, indicates its aggregate voting interest in Telix has fallen below the substantial holding threshold, signalling a reduction in its exposure to the biotech company for investors tracking cross-holdings and ownership shifts.
The notice, signed by Company Secretary Linda Matthews, updates the market following a previous substantial holding disclosure in March 2026. While specific transaction details are contained in annexures, the filing confirms Challenger’s exit from substantial holder status, refining the picture of institutional ownership in Telix and potentially affecting how both companies are positioned in the portfolios of institutional investors.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$8.00 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
More about Challenger
Challenger Limited is an Australian financial services group headquartered in Sydney, with operations across major state capitals. Through its various licensed entities, Challenger focuses on retirement income, life insurance, investment management and related securitisation and mortgage management services for institutional and retail clients.
Average Trading Volume: 1,832,681
Technical Sentiment Signal: Buy
Current Market Cap: A$5.69B
For an in-depth examination of CGF stock, go to TipRanks’ Overview page.